Pretreatment quality of life, performance status and their relation to treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy: results from the prospective randomized ADEBAR trial
- First Online:
- 222 Downloads
Health-related quality of life (QoL) is a self-assessed construct indicating how people feel in regard to aspects of their health. Performance status (PS) is evaluated by the treating physician. We examined whether pretreatment QoL and PS are related to subsequent treatment discontinuation and treatment changes in high-risk breast cancer patients receiving chemotherapy.
We conducted a prospective cohort study with data from a randomized phase III trial comparing FEC- and EC-DOC-chemotherapy in patients with primary breast cancer (ADEBAR). We examined the patient’s request to discontinue the study, discontinuation due to toxicity, the prolongation of therapy, and dose reduction. Baseline QoL was assessed using the EORTC QLQ-C30. PS was evaluated using the Eastern Cooperative Oncology Group Scale (ECOG). Four QoL scales were selected prior to analysis as outcomes: global health, physical functioning, emotional functioning, and fatigue. Multivariate binary logistic regression analyses were used to test for differences within the independent variables.
1322 patients were included. 1094 (82.8 %) patients completed therapy according to protocol. 6.3 % stopped therapy due to toxicity and 4.4 % refused treatment. Global health was not related to any of the four QoL outcomes. Physical functioning had the strongest impact on QoL, when comparing the fittest group to the lowest quintile [OR 2.14 (95 % CI 1.00–4.60)]. ECOG 0 compared to worse than 1 was strongly correlated to therapy discontinuation due to toxicity [OR 20.15 (95 % CI 9.48–42.83)] and treatment refusal [OR 8.32 (95 % CI 3.81–18.14)].
Pretreatment QoL, especially physical functioning, is associated with subsequent therapy discontinuation due to toxicity and with changes of the treatment protocol. Pretreatment performance status is strongly associated with therapy discontinuation due to toxicity and with treatment refusal.
KeywordsQuality of life Performance status Treatment discontinuation Breast cancer Chemotherapy
- 2.Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, et al. Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst. 1995;87(17):1316–22.CrossRefPubMedGoogle Scholar
- 3.Coates AS, Hürny C, Peterson HF, Bernhard J, Castiglione-Gertsch M, Gelber RD, International Breast Cancer Study Group, et al. Quality-of-life scores predict outcome in metastatic but not early breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18(22):3768–74.Google Scholar
- 4.Kramer JA, Curran D, Piccart M, de Haes JC, Bruning P, Klijn J, et al. Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer. Eur J Cancer Oxf Engl. 2000;36(12):1498–506.CrossRefGoogle Scholar
- 9.Combination chemotherapy in treating women with breast cancer, ClinicalTrials.gov Identifier: NCT00047099.Google Scholar
- 10.Janni W, et al. Sequential treatment with epirubicin/cyclophosphamide, followed by docetaxel versus FEC120 in the adjuvant treatment of node-positive breast cancer patients: final survival analysis of the German ADEBAR phase III study. J Clin Oncol. 2012;30(suppl):abstr 1081.Google Scholar
- 12.Fayers P, Aaronson N, Bjordal K, Groenvold M. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer; 2001.Google Scholar
- 13.IBM Corp. IBM SPSS Statistics for Windows, Version 22.0. Armonk: IBM Corp; 2013.Google Scholar
- 14.Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A. EORTC QLQ-C30 reference values. Brussels: European Organisation for Research and Treatment of Cancer; 2008.Google Scholar
- 15.You J, Shi Z. Study on the relationship among the international scales for quality of life evaluation in patients with lung cancer, the East Cooperative Oncology Group Status and Lung Cancer Symptoms Lists of TCM. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi Chin J Integr Tradit West Med Zhongguo Zhong Xi Yi Jie He Xue Hui Zhongguo Zhong Yi Yan Jiu Yuan Zhu Ban. 2005;25(7):595–9.Google Scholar
- 17.Levine MN, Guyatt GH, Gent M, De Pauw S, Goodyear MD, Hryniuk WM, et al. Quality of life in stage II breast cancer: an instrument for clinical trials. J Clin Oncol Off J Am Soc Clin Oncol. 1988;6(12):1798–810.Google Scholar